Abarelix

Abarelix Uses, Dosage, Side Effects, Food Interaction and all others data.

Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market.

Used in the palliative treatment of advanced prostate cancer. Abarelix is a luteinizing hormone agonist that results in suppression of testicular or follicular steroidogenesis.

Abarelix
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Abarelix
Availability	Discontinued
Generic	Abarelix
Abarelix Other Names	Abarelix
Related Drugs	estradiol, Premarin, Xtandi, Casodex, Zytiga, Lynparza
Type
Formula	C₇₂H₉₅ClN₁₄O₁₄
Weight	Average: 1416.09 Monoisotopic: 1414.6840715
Protein binding	96-99%
Groups	Approved, Investigational, Withdrawn
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

For palliative treatment of advanced prostate cancer.

How Abarelix works

Abarelix binds to the gonadotropin releasing hormone receptor and acts as a potent inhibitor of gonadotropin secretion.

Toxicity

The maximum tolerated dose of abarelix has not been determined. The maximum dose used in clinical studies was 150 mg. There have been no reports of accidental overdose with abarelix.

Abarelix Drug Interaction

Minor: sulfamethoxazole / trimethoprim, sulfamethoxazole / trimethoprimUnknown: acetaminophen, acetaminophen, aspirin, aspirin, alprazolam, alprazolam, pseudoephedrine / triprolidine, pseudoephedrine / triprolidine, carboplatin, carboplatin, clotrimazole, clotrimazole, indium pentetate in-111, indium pentetate in-111

Elimination Route

Following IM administration of 100 mg, abarelix is absorbed slowly with a mean peak concentration of 43.4 ng/mL observed approximately 3 days after the injection.